https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Wendy Kennedy
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Wendy Kennedy2022-10-03 13:31:112022-10-04 11:08:41Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Wendy Kennedy
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Wendy Kennedy2022-10-03 13:29:102022-10-03 13:29:10Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-08-17 15:09:312022-08-17 15:09:31AUT00206, a Novel Kv3.1/3.2 Positive Modulator, Normalizes Gamma Oscillations in Patients with Schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-07-22 17:17:402022-08-17 15:24:09AUT00206, a Novel Kv3.1/3.2 Positive Modulator, Normalizes Gamma Oscillations in Patients with Schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-07-22 17:16:082022-08-17 15:24:17AUT00206, a Novel Kv3.1/3.2 Positive Modulator, Normalizes Gamma Oscillations in Patients with Schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-07-22 17:14:012022-08-17 15:24:24AUT00206, a Novel Treatment for Schizophrenia, Improves Auditory Mismatch Negativity and Hearing Performance in Patients
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-07-22 17:12:132022-08-17 15:24:33AUT00206, a Novel Treatment for Schizophrenia, Improves Auditory Mismatch Negativity and Hearing Performance in Patients
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-07-22 17:10:502022-08-17 15:24:40Improvement in Otoacoustic Emissions and Speech-in-Noise Performance Among Patients with Schizophrenia treated with AUT00206
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-07-22 17:08:522022-08-17 15:24:47AUT00206, a novel Kv3 channel modulator, reduces ketamine-induced BOLD signalling in healthy male volunteers: a randomised placebo-controlled crossover trial
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
0
0
Editor
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg
Editor2022-07-22 17:04:492022-08-17 15:24:54Early clinical evaluation of AUT00206, a novel and selective Kv3 channel modulator for the treatment of schizophrenia
Scroll to top